Regarding the MAPK signaling pathway, inhibition of mitogen-activated protein kinase kinase (MEK) by trametinib contributed to mitigating effects on glioblastoma cell growth in preclinical models [10] and was used in combination with dabrafenib in a clinical trial treating glioblastoma with BRAFV600E mutations [11]. The gene discussed is WNK2; the disease is glioblastoma.